Papers

1

Total Citations

110

H-Index

1

About

Amy Hsu is a leading figure in bioprocess engineering, whose work has fundamentally advanced the high-throughput development of cell culture processes for therapeutic proteins. Her research focuses on the scalability and reproducibility of micro-bioreactor systems, addressing a critical bottleneck in the biopharmaceutical industry: the need to rapidly and efficiently optimize cell culture conditions for drug and vaccine candidates. Hsu’s most impactful contribution is her seminal 2010 paper, “Novel micro‐bioreactor high throughput technology for cell culture process development,” which has garnered over 110 citations. This work provided the first rigorous demonstration that fed-batch Chinese hamster ovary (CHO) cultures in a micro-scale system could reliably replicate the performance of traditional, larger-scale bioreactors. By validating this high-throughput platform, Hsu’s research has empowered scientists to explore a vastly larger experimental design space, dramatically accelerating process development timelines while reducing resource consumption. Her achievements have established a new standard for early-stage bioprocess characterization, making her a pivotal innovator in the drive toward more agile and cost-effective biologics manufacturing.

Research Focus

Key Achievements

1
H-Index
1
Papers
110
Total Citations
110
Avg Citations/Paper
🏆 Most Cited Paper
Novel micro‐bioreactor high throughput technology for cell culture process development: Reproducibility and scalability assessment of fed‐batch CHO cultures
110 citations · 2010
📈 Most Prolific Year: 2010 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago